Exporting Healthcare Equipment & Pharmaceuticals to Brazil

Brazil is the largest healthcare market in Latin America, with total health spending reaching approximately 9.5% of GDP in 2022, according to the World Bank. For US exporters of healthcare equipment and pharmaceuticals, Brazil represents a substantial opportunity driven by an aging population, rising chronic disease prevalence, and ongoing investments in public and private healthcare infrastructure. However, navigating Brazil’s complex regulatory environment, local content requirements, and import procedures requires careful planning. This page provides a strategic overview for US companies looking to enter or expand in the Brazilian healthcare market.

Local Market Size and Demand

Brazil’s healthcare equipment and pharmaceutical market was valued at over $30 billion in 2023, with imports accounting for a significant share. The country relies heavily on imported medical devices, particularly high-tech equipment such as diagnostic imaging systems, surgical instruments, and orthopedic implants. According to the International Trade Administration, Brazil imported approximately $5.5 billion in medical devices from the United States in 2022, making the US the second-largest supplier after China. The pharmaceutical sector is also robust, with Brazil importing about $8 billion in pharmaceutical products annually, of which US-origin products represent roughly 15%. Demand is fueled by Brazil’s universal healthcare system (SUS), which serves over 150 million people, and a growing private health insurance market covering an additional 50 million individuals. Key growth areas include cardiology, oncology, diabetes care, and hospital infrastructure modernization.

Import Process

Importing healthcare equipment and pharmaceuticals into Brazil involves several mandatory steps. All medical devices must be registered with the Brazilian Health Regulatory Agency (ANVISA), a process that can take six to eighteen months depending on the product risk classification. Pharmaceuticals require similar registration, with additional requirements for clinical trial data and Good Manufacturing Practices (GMP) certification. Import duties vary: medical devices face an average tariff of 14–16%, while pharmaceutical products are often subject to lower rates, sometimes zero under the Lista de Exceções à Tarifa Externa Comum (Letec). Beyond tariffs, importers must contend with the Programa de Integração Social (PIS) and Contribuição para o Financiamento da Seguridade Social (COFINS) contributions, which add approximately 9.25% to the cost. The Brazilian government also incentivizes local production through the Industrial Policy for Health (PIS), which can reduce import taxes for companies that commit to technology transfer or local manufacturing. US exporters should work with experienced customs brokers and legal advisors to ensure compliance with ANVISA regulations and to navigate the complex tax structure.

Key Buyers and Distributors

The Brazilian healthcare market is characterized by a mix of public and private buyers. The largest single purchaser is the Ministry of Health, which procures equipment and pharmaceuticals for the SUS through public tenders (licitações). Private hospital networks, such as Rede D’Or São Luiz, Hospital Israelita Albert Einstein, and UnitedHealth Group’s Brazilian operations, represent significant buyers of high-end medical equipment. Distributors play a critical role in market access, as many international suppliers rely on local partners for registration, warehousing, and sales. Major distributors include DASA (Diagnósticos da América), which distributes diagnostic equipment; Cremer, a leading supplier of hospital products; and Profarma, a pharmaceutical distributor. For US companies, establishing relationships with these distributors or directly with large hospital groups is often the most effective route to market. Trade shows such as Hospitalar (São Paulo) and FCE Pharma (São Paulo) are key venues for networking and showcasing products.

US Supplier Advantages

US healthcare equipment and pharmaceutical suppliers enjoy several competitive advantages in Brazil. American products are widely perceived as high-quality, innovative, and reliable, which aligns with the preferences of Brazil’s sophisticated private healthcare sector. US brands benefit from strong intellectual property protections under the US-Brazil bilateral agreements, reducing the risk of counterfeiting. Additionally, the US and Brazil have a longstanding trade relationship, with the US consistently ranking among Brazil’s top three suppliers of medical goods. US exporters can leverage the Export-Import Bank of the United States (EXIM) for financing and the U.S. Commercial Service for market intelligence and matchmaking. However, US companies must be prepared to compete with lower-cost suppliers from China and Europe, as well as with local manufacturers that benefit from government procurement preferences under the PIS. Emphasizing after-sales service, training, and long-term partnerships can differentiate US suppliers in this market.

Coppermont Advisory

Coppermont helps US healthcare equipment and pharmaceutical companies navigate the Brazilian market with confidence. Our services include regulatory strategy for ANVISA registration, partner identification and due diligence, customs and tax optimization, and market entry planning. We work with US exporters to assess product-market fit, understand local content requirements, and build relationships with key buyers and distributors. Whether you are a medical device manufacturer seeking to register your first product or a pharmaceutical company expanding your portfolio, Coppermont provides the local expertise and strategic guidance needed to succeed in Brazil. Contact us to learn how we can support your export growth to Latin America’s largest healthcare market.